These knockin mice express a tamoxifen-inducible cre recombinase from the endogenous promoter/enhancer elements of the preproenkephalin locus. When induced, cre activity is observed in the striatum, olfactory tubercle, and sparse cells in the dentate gyrus and cortex.
Hongkui Zeng, Allen Institute for Brain Science
Genetic Background | Generation |
---|---|
|
Allele Type | Gene Symbol | Gene Name |
---|---|---|
Targeted (Recombinase-expressing, Inducible) | Penk | preproenkephalin |
Mice heterozygous for the Penk-2A-CreERT2-D targeted mutation (also called Penk-2A-CreERT2-Δ or Penk-2A-CreERT2-Δneo) are viable and fertile. The Penk-2A-CreERT2-D targeted mutation has an in-frame F2A peptide cleavage signal and a CreERT2 fusion gene (CreERT2 fusion protein) inserted downstream of the preproenkephalin translational STOP codon.
As such, Penk-2A-CreERT2-D mice have both endogenous gene and CreERT2 fusion protein expression directed to Penk-expressing cells by the endogenous promoter/enhancer elements of the preproenkephalin locus. CreERT2 fusion gene activity is inducible; observed following tamoxifen administration. When Penk-2A-CreERT2-D mice are bred with mice containing loxP-flanked sequences, tamoxifen-inducible Cre-mediated recombination will result in deletion of floxed sequences in the Penk-expressing cells of the double mutant offspring.
Specifically, the donating investigator reports that Cre recombinase expression (in situ hybridization) is strong in striatum, in olfactory tubercle, and in sparse dentate gyrus and cortex. Furthermore, Cre recombinase expression (in situ hybridization) is observed weakly throughout the brain. Tamoxifen-inducible Cre recombinase activity recapitulates the endogenous Penk expression pattern, but with a relatively low efficiency of induction. The donating investigator reports no Cre recombinase expression (no reporter gene expression) is observed prior to tamoxifen exposure. The donating investigator did not examine CreERT2 activity in tissues other than brain, and did not attempt to generate homozygous mice to date (July 2013).
For characterization information, see images at the Allen Institute for Brain Science website (Penk-2A-CreERT2 images).
The Cre-ERT2 fusion protein consists of Cre recombinase fused to a triple mutant form of the human estrogen receptor which does not bind its natural ligand (17β-estradiol) at physiological concentrations but will bind the synthetic estrogen receptor ligands 4-hydroxytamoxifen (OHT or tamoxifen) and, with lesser sensitivity, ICI 182780. Restricted to the cytoplasm, Cre-ERT2 can only gain access to the nuclear compartment after exposure to tamoxifen. To counteract the mixed estrogen agonist effects of tamoxifen injections, which can result in late fetal abortions in pregnant mice, progesterone may be coadministered.
The Penk-2A-CreERT2-D targeted mutation (also called Penk-2A-CreERT2-Δ or Penk-2A-CreERT2-Δneo) has a CreERT2 fusion gene inserted downstream of the preproenkephalin translational STOP codon, with both genes separated by an in-frame F2A peptide cleavage signal (to promote expression of both individual genes). The specific details are below.
The targeting vector contained, from 5' to 3',
a partial Penk intron 1 sequence containing an frt3 site,
a partial Penk exon 2 sequence up to (but not including) the endogenous stop codon,
a foot-and-mouth disease virus self-cleaving 2A peptide sequence (FMDV 2A or F2A; to promote individual expression the genes before and after it) that is in-frame with the Penk coding sequence,
a CreERT2 fusion gene (Cre-ERT2; Cre recombinase fused to a G400V/M543A/L544A triple mutation of the human estrogen receptor ligand binding domain) that is in-frame with the Penk coding sequence,
a bovine growth hormone polyA signal,
an AttB site,
a PGK-Neo-polyA cassette,
an frt5 site,
an mRNA splice acceptor,
the 3' portion of the hygromycin gene with SV40 polyA signal,
an AttP site,
and genomic sequence from the Penk locus starting 509 bp downstream of the endogenous stop codon (to create a 511 bp deletion downstream of, and including, the stop codon).
This targeting vector was electroporated into (129S6/SvEvTac x C57BL/6)F1-derived G4 embryonic stem (ES) cells. Correctly targeted ES cells were injected into recipient blastocysts. The resulting chimeric animals were bred to PhiC31-expressing mice (C57BL/6J congenic background; see Stock No. 007743) to delete the AttB/AttP-flanked sequences (PGK-neo-polyA::frt5::mRNA splice acceptor::3'hygro::SV40 polyA) and replace it with the recombined AttB/AttP site (AttL). The resulting Penk-2A-CreERT2-D mice were bred with C57BL/6J wildtype mice for several generations (and the PhiC31 transgene was removed) prior to sending generation N7F1 males to The Jackson Laboratory Repository in 2013. During backcrossing, the Y chromosome may not have been fixed to the C57BL/6J genetic background. Upon arrival, males were used to cryopreserve sperm. To establish the living Penk-2A-CreERT2-D mouse colony, an aliquot of the frozen sperm was used to fertilize oocytes from C57BL/6J inbred females (Stock No. 000664).
Expressed Gene | cre/ERT2, Cre recombinase and estrogen receptor 1 (human) fusion gene, |
---|---|
Site of Expression | Cre recombinase expression (in situ hybridization) is strong in striatum, in olfactory tubercle, and in sparse dentate gyrus and cortex, and is observed weakly throughout the brain. |
Allele Name | targeted mutation 1.1, Hongkui Zeng |
---|---|
Allele Type | Targeted (Recombinase-expressing, Inducible) |
Allele Synonym(s) | Penk-2A-CreERT2; Penk-2A-CreERT2-DeltaNeo |
Gene Symbol and Name | Penk, preproenkephalin |
Gene Synonym(s) | |
Expressed Gene | cre/ERT2, Cre recombinase and estrogen receptor 1 (human) fusion gene, |
Site of Expression | Cre recombinase expression (in situ hybridization) is strong in striatum, in olfactory tubercle, and in sparse dentate gyrus and cortex, and is observed weakly throughout the brain. |
Strain of Origin | (129S6/SvEvTac x C57BL/6NCrl)F1 |
Chromosome | 4 |
Molecular Note | A targeting vector contained a partial Penk intron 1 sequence containing an frt3 site, a partial Penk exon 2 sequence up to (but not including) the endogenous stop codon, a self-cleaving T2A sequence in-frame with the Nxph4 coding sequence, a cre/ERT2 fusion gene, a bovine growth hormone polyA signal, an AttB site, a PGK-Neo-polyA cassette, an frt5 site, an mRNA splice acceptor, the 3' portion of the hygromycin gene with SV40 polyA signal, an AttP site and genomic sequence from the Penk locus starting 509 bp downstream of the endogenous stop codon (to create a 511 bp deletion including, the stop codon). This targeting vector was electroporated into G4 ES cells. Correctly targeted ES cells were injected into recipient blastocysts. The resulting chimeric animals were bred to PhiC31-expressing mice to delete the AttB/AttP-flanked sequences and replace it with the recombined AttB/AttP site (AttL). |
When maintaining a live colony, heterozygous mice may be bred to wildtype mice from the colony or to C57BL/6J inbred mice (Stock No. 000664). The phenotype of homozygous mice has not yet been determined (July 2013).
When using the Penk-2A-CreERT2-D mouse strain in a publication, please cite the originating article(s) and include JAX stock #022862 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Heterozygous or Wildtype for Penk<tm1.1(cre/ERT2)Hze> |
Frozen Mouse Embryo | B6.Cg-Penk<tm1.1(cre/ERT2)Hze>/J | $2595.00 |
Frozen Mouse Embryo | B6.Cg-Penk<tm1.1(cre/ERT2)Hze>/J | $2595.00 |
Frozen Mouse Embryo | B6.Cg-Penk<tm1.1(cre/ERT2)Hze>/J | $3373.50 |
Frozen Mouse Embryo | B6.Cg-Penk<tm1.1(cre/ERT2)Hze>/J | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.